Immunotherapy is a promising strategy to treat refractory diseases.
TriApex has established the Cell Biology & Immunology Evaluation Department, covering the exploration of immune response mechanisms from drug discovery, preclinical research to all phases of clinical trials. We are committed to providing one-stop scientific services for products including immune cell therapies, immunomodulatory drugs, and vaccines, and also use existing platforms and technologies to enable the development of immune system-related drugs.
Introduction of ServicesPlatform | Disease | Product |
Immunophenotyping Target Occupancy (Receptor Occupancy) ELISPOT (Cytokines and Immunoglobulins) Cytokines In vitro Cytokine Release Assay Cytotoxicity (ADCC/CDC/ADCP, NK activity, T cell cytotoxicity) Non-immune Cell Phenotyping | Tumors (Solid tumor, hematologic malignancy) Autoimmune Diseases Infection and Secondary Infection | Vaccine (mRNA, recombinant protein) Immunomodulatory Drug Adoptive Cell Therapy Stem Cell therapy |
ApplicationsThe Cell Biology & Immunology Evaluation Department of TriApex can provide public preventive vaccine research, tumor preventive and therapeutic vaccine research, and CD cell immunity research for various specialized diseases such as oncology, rheumatology, infection, and preventive health care.
Official WeChat account
Official video account
Regulatory Policies
Project Management
Global
